{ "FullStudy":{ "Rank":217957, "Study":{ "ProtocolSection":{ "IdentificationModule":{ "NCTId":"NCT01514630", "OrgStudyIdInfo":{ "OrgStudyId":"60398" }, "Organization":{ "OrgFullName":"University of Utah", "OrgClass":"OTHER" }, "BriefTitle":"Creatine as a Treatment Option for Depression in Methamphetamine Using Females", "OfficialTitle":"Creatine as a Treatment Option for Depression in Methamphetamine Using Females" }, "StatusModule":{ "StatusVerifiedDate":"June 2015", "OverallStatus":"Completed", "ExpandedAccessInfo":{ "HasExpandedAccess":"No" }, "StartDateStruct":{ "StartDate":"January 2013" }, "PrimaryCompletionDateStruct":{ "PrimaryCompletionDate":"December 2014", "PrimaryCompletionDateType":"Actual" }, "CompletionDateStruct":{ "CompletionDate":"February 2015", "CompletionDateType":"Actual" }, "StudyFirstSubmitDate":"January 12, 2012", "StudyFirstSubmitQCDate":"January 17, 2012", "StudyFirstPostDateStruct":{ "StudyFirstPostDate":"January 23, 2012", "StudyFirstPostDateType":"Estimate" }, "ResultsFirstSubmitDate":"May 14, 2015", "ResultsFirstSubmitQCDate":"June 9, 2015", "ResultsFirstPostDateStruct":{ "ResultsFirstPostDate":"June 29, 2015", "ResultsFirstPostDateType":"Estimate" }, "LastUpdateSubmitDate":"June 9, 2015", "LastUpdatePostDateStruct":{ "LastUpdatePostDate":"June 29, 2015", "LastUpdatePostDateType":"Estimate" } }, "SponsorCollaboratorsModule":{ "ResponsibleParty":{ "ResponsiblePartyType":"Sponsor-Investigator", "ResponsiblePartyInvestigatorFullName":"Perry Renshaw", "ResponsiblePartyInvestigatorTitle":"Professor of Psychiatry", "ResponsiblePartyInvestigatorAffiliation":"University of Utah" }, "LeadSponsor":{ "LeadSponsorName":"Perry Renshaw", "LeadSponsorClass":"OTHER" } }, "OversightModule":{ "OversightHasDMC":"Yes" }, "DescriptionModule":{ "BriefSummary":"Methamphetamine (MA) is a psychostimulant drug with high abuse potential. MA can be smoked, snorted, injected or ingested orally to produce a release of high levels of dopamine into the brain and reduction of dopamine uptake. Its use results in feelings of pleasure, increased energy, and greater alertness lasting up to 12 hours. In 2010, the National Survey on Drug Use and Health reported that 353,000 Americans aged 12 or older reported being current MA users. Over the past decade MA use rates have fluctuated with current use rates on the decline; however, importantly, even though overall use rates are declining, use rates among males and females are approaching equal proportions. This use rate pattern is unlike other drugs of abuse, which typically demonstrate males using more than females. In some states, more females than males consider MA as their drug of choice. Namely, in a 2010 report in the state of Utah, more females were diagnosed with MA as a primary substance of abuse than males upon admission to treatment.\n\nDepression and MA use are highly comorbid. The relationship between MA use and depression is likely bidirectional, with MA use causing changes in mood and being used as a self-medicating behavior to reduce symptoms of depression. Several studies have shown that depression rates are higher in MA-using females compared to their male counterparts. It is likely that neurobiological and psychosocial mechanisms contribute to increased incidence of depressive symptoms in females.\n\nNo clear treatment model exists to suggest how the comorbidity of depression and MA use is best managed. In studies of antidepressants for treatment of MA withdrawal and dependence, findings have suggested that antidepressants are ineffective for treating depressive symptoms.\n\nCreatine is an organic acid occurring naturally in vertebrates, where it takes part in energy homeostasis in tissues with fluctuating energy demands. Exogenous creatine has been shown to increase brain concentrations of PCr. Neuroimaging studies of creatine have shown increased brain phosphocreatine (PCr) content with creatine administration. Therefore, we hypothesize that oral creatine administration will increase PCr levels and reduce depressive symptoms in a sample of depressed female MA users. This hypothesis will be tested by a within subjects design by giving depressed MA using females oral creatine for eight weeks and measuring PCr pre- and post-treatment with magnetic resonance spectroscopy. Moreover, depressive symptoms will be measured by administration of the Hamilton Depression Rating Scale twice weekly during the course of creatine treatment." }, "ConditionsModule":{ "ConditionList":{ "Condition":[ "Depression", "Substance Abuse", "Substance Use", "Neuroimaging", "Dual Diagnosis" ] } }, "DesignModule":{ "StudyType":"Interventional", "PhaseList":{ "Phase":[ "Phase 4" ] }, "DesignInfo":{ "DesignInterventionModel":"Single Group Assignment", "DesignPrimaryPurpose":"Treatment", "DesignMaskingInfo":{ "DesignMasking":"None (Open Label)" } }, "EnrollmentInfo":{ "EnrollmentCount":"14", "EnrollmentType":"Actual" } }, "ArmsInterventionsModule":{ "ArmGroupList":{ "ArmGroup":[ { "ArmGroupLabel":"Creatine monohydrate", "ArmGroupType":"Experimental", "ArmGroupDescription":"14 female depressed methamphetamine users received 5 grams of creatine monohydrate daily for eight weeks.", "ArmGroupInterventionList":{ "ArmGroupInterventionName":[ "Drug: Creatine monohydrate" ] } } ] }, "InterventionList":{ "Intervention":[ { "InterventionType":"Drug", "InterventionName":"Creatine monohydrate", "InterventionDescription":"Five grams of creatine monohydrate will be administered for eight weeks.", "InterventionArmGroupLabelList":{ "InterventionArmGroupLabel":[ "Creatine monohydrate" ] } } ] } }, "OutcomesModule":{ "PrimaryOutcomeList":{ "PrimaryOutcome":[ { "PrimaryOutcomeMeasure":"HAMD Rating Scores", "PrimaryOutcomeDescription":"Eight weeks of oral creatine supplementation will result in improvements in Hamilton Depression Rating Scale (HAMD) in female methamphetamine users. HAMD scoring is based on 17 items. Minimum score is 0 and maximum 52. A score of 0-7 is considered to be normal. Scores of 20 or higher indicate moderate or severe depression.\n\n0-7 = Normal 8-13 = Mild Depression 14-18 = Moderate Depression 19-22 = Severe Depression\n\n≥ 23 = Very Severe Depression", "PrimaryOutcomeTimeFrame":"Over the course of eight weeks. Depression rating scores will be measured weekly for eight weeks for each subject enrolled." } ] } }, "EligibilityModule":{ "EligibilityCriteria":"Inclusion Criteria:\n\nFemale gender, ages 18-64 years inclusive\nDiagnosis of MA dependence or abuse within the past 12 months, with MA preferred drug of abuse, identified by the SCID-I-RV\nCurrent diagnosis of Major Depressive Disorder identified by the SCID-I-RV\nCurrent HAM-D17 score of > 15\n\nExclusion Criteria:\n\nDiagnosis of bipolar disorder, schizophrenia, or schizoaffective disorder, identified by the SCID-I-RV\nHistory of or current diagnosis of renal disease, such as chronic renal failure, acute renal failure or end stage renal disease\nDiabetes type I or II\nColitis or diverticulitis\nSeizure disorder\nCurrent serious suicide risk identified by the Columbia Severity Suicide Rating Severity\nCurrent treatment with an antipsychotic, mood stabilizer, or antidepressant\nPositive HIV test\nActive Hepatitis C\nContraindication to magnetic resonance scan", "HealthyVolunteers":"No", "Gender":"Female", "MinimumAge":"13 Years", "MaximumAge":"64 Years", "StdAgeList":{ "StdAge":[ "Child", "Adult" ] } }, "ContactsLocationsModule":{ "OverallOfficialList":{ "OverallOfficial":[ { "OverallOfficialName":"Tracy Hellem, RN", "OverallOfficialAffiliation":"The College of Nursing & Brain Institute, University of Utah", "OverallOfficialRole":"Principal Investigator" },{ "OverallOfficialName":"Perry Renshaw, MD, PhD, MBA", "OverallOfficialAffiliation":"Department of Psychiatry, University of Utah", "OverallOfficialRole":"Study Director" } ] }, "LocationList":{ "Location":[ { "LocationFacility":"The Brain Institute of the University of Utah", "LocationCity":"Salt Lake City", "LocationState":"Utah", "LocationZip":"84108", "LocationCountry":"United States" } ] } }, "ReferencesModule":{ "ReferenceList":{ "Reference":[ { "ReferencePMID":"26457568", "ReferenceType":"derived", "ReferenceCitation":"Hellem TL, Sung YH, Shi XF, Pett MA, Latendresse G, Morgan J, Huber RS, Kuykendall D, Lundberg KJ, Renshaw PF. Creatine as a Novel Treatment for Depression in Females Using Methamphetamine: A Pilot Study. J Dual Diagn. 2015;11(3-4):189-202. doi: 10.1080/15504263.2015.1100471." } ] } } }, "ResultsSection":{ "ParticipantFlowModule":{ "FlowGroupList":{ "FlowGroup":[ { "FlowGroupId":"FG000", "FlowGroupTitle":"Creatine Monohydrate", "FlowGroupDescription":"14 female depressed methamphetamine users received 5 grams of creatine monohydrate daily for eight weeks. Participants were seen twice weekly after creatine was initiated. All participants met SCID-I/P criteria for lifetime methamphetamine dependence or for current methamphetamine dependence. After consent was obtained, the principal investigator administered the SCID-I/P and HAMD, and if a female met SCID-I/P criteria and scored > 15 on the HAMD, the following additional screening data were collected: Beck Anxiety Inventory, C-SSRS , vital signs, concomitant medications, self-report drug use over the past 48 hours for cigarettes, alcohol, cocaine, methamphetamine, marijuana, heroin and prescription controlled substances, urine drug screen for methamphetamine, opiates, benzodiazepines, marijuana and cocaine, pregnancy testing and attendance in outpatient treatment and/or 12 step programs." } ] }, "FlowPeriodList":{ "FlowPeriod":[ { "FlowPeriodTitle":"Overall Study", "FlowMilestoneList":{ "FlowMilestone":[ { "FlowMilestoneType":"STARTED", "FlowAchievementList":{ "FlowAchievement":[ { "FlowAchievementGroupId":"FG000", "FlowAchievementNumSubjects":"14" } ] } },{ "FlowMilestoneType":"COMPLETED", "FlowAchievementList":{ "FlowAchievement":[ { "FlowAchievementGroupId":"FG000", "FlowAchievementNumSubjects":"11" } ] } },{ "FlowMilestoneType":"NOT COMPLETED", "FlowAchievementList":{ "FlowAchievement":[ { "FlowAchievementGroupId":"FG000", "FlowAchievementNumSubjects":"3" } ] } } ] } } ] } }, "BaselineCharacteristicsModule":{ "BaselineGroupList":{ "BaselineGroup":[ { "BaselineGroupId":"BG000", "BaselineGroupTitle":"Creatine Monohydrate", "BaselineGroupDescription":"14 female depressed methamphetamine users will receive 5 grams of creatine monohydrate daily for eight weeks.\n\nCreatine monohydrate: Five grams of creatine monohydrate will be administered for eight weeks." } ] }, "BaselineDenomList":{ "BaselineDenom":[ { "BaselineDenomUnits":"Participants", "BaselineDenomCountList":{ "BaselineDenomCount":[ { "BaselineDenomCountGroupId":"BG000", "BaselineDenomCountValue":"14" } ] } } ] }, "BaselineMeasureList":{ "BaselineMeasure":[ { "BaselineMeasureTitle":"Age, Categorical", "BaselineMeasureParamType":"Count of Participants", "BaselineMeasureUnitOfMeasure":"Participants", "BaselineClassList":{ "BaselineClass":[ { "BaselineCategoryList":{ "BaselineCategory":[ { "BaselineCategoryTitle":"<=18 years", "BaselineMeasurementList":{ "BaselineMeasurement":[ { "BaselineMeasurementGroupId":"BG000", "BaselineMeasurementValue":"0" } ] } },{ "BaselineCategoryTitle":"Between 18 and 65 years", "BaselineMeasurementList":{ "BaselineMeasurement":[ { "BaselineMeasurementGroupId":"BG000", "BaselineMeasurementValue":"14" } ] } },{ "BaselineCategoryTitle":">=65 years", "BaselineMeasurementList":{ "BaselineMeasurement":[ { "BaselineMeasurementGroupId":"BG000", "BaselineMeasurementValue":"0" } ] } } ] } } ] } },{ "BaselineMeasureTitle":"Age, Continuous", "BaselineMeasureParamType":"Mean", "BaselineMeasureDispersionType":"Standard Deviation", "BaselineMeasureUnitOfMeasure":"years", "BaselineClassList":{ "BaselineClass":[ { "BaselineCategoryList":{ "BaselineCategory":[ { "BaselineMeasurementList":{ "BaselineMeasurement":[ { "BaselineMeasurementGroupId":"BG000", "BaselineMeasurementValue":"37.4", "BaselineMeasurementSpread":"9.9" } ] } } ] } } ] } },{ "BaselineMeasureTitle":"Sex: Female, Male", "BaselineMeasureParamType":"Count of Participants", "BaselineMeasureUnitOfMeasure":"Participants", "BaselineClassList":{ "BaselineClass":[ { "BaselineCategoryList":{ "BaselineCategory":[ { "BaselineCategoryTitle":"Female", "BaselineMeasurementList":{ "BaselineMeasurement":[ { "BaselineMeasurementGroupId":"BG000", "BaselineMeasurementValue":"14" } ] } },{ "BaselineCategoryTitle":"Male", "BaselineMeasurementList":{ "BaselineMeasurement":[ { "BaselineMeasurementGroupId":"BG000", "BaselineMeasurementValue":"0" } ] } } ] } } ] } },{ "BaselineMeasureTitle":"Region of Enrollment", "BaselineMeasureParamType":"Number", "BaselineMeasureUnitOfMeasure":"participants", "BaselineClassList":{ "BaselineClass":[ { "BaselineClassTitle":"United States", "BaselineCategoryList":{ "BaselineCategory":[ { "BaselineMeasurementList":{ "BaselineMeasurement":[ { "BaselineMeasurementGroupId":"BG000", "BaselineMeasurementValue":"14" } ] } } ] } } ] } } ] } }, "OutcomeMeasuresModule":{ "OutcomeMeasureList":{ "OutcomeMeasure":[ { "OutcomeMeasureType":"Primary", "OutcomeMeasureTitle":"HAMD Rating Scores", "OutcomeMeasureDescription":"Eight weeks of oral creatine supplementation will result in improvements in Hamilton Depression Rating Scale (HAMD) in female methamphetamine users. HAMD scoring is based on 17 items. Minimum score is 0 and maximum 52. A score of 0-7 is considered to be normal. Scores of 20 or higher indicate moderate or severe depression.\n\n0-7 = Normal 8-13 = Mild Depression 14-18 = Moderate Depression 19-22 = Severe Depression\n\n≥ 23 = Very Severe Depression", "OutcomeMeasureReportingStatus":"Posted", "OutcomeMeasureParamType":"Mean", "OutcomeMeasureDispersionType":"Standard Deviation", "OutcomeMeasureUnitOfMeasure":"Units on a scale", "OutcomeMeasureTimeFrame":"Over the course of eight weeks. Depression rating scores will be measured weekly for eight weeks for each subject enrolled.", "OutcomeGroupList":{ "OutcomeGroup":[ { "OutcomeGroupId":"OG000", "OutcomeGroupTitle":"Creatine Monohydrate", "OutcomeGroupDescription":"14 female depressed methamphetamine users will receive 5 grams of creatine monohydrate daily for eight weeks.\n\nCreatine monohydrate: Five grams of creatine monohydrate will be administered for eight weeks." } ] }, "OutcomeDenomList":{ "OutcomeDenom":[ { "OutcomeDenomUnits":"Participants", "OutcomeDenomCountList":{ "OutcomeDenomCount":[ { "OutcomeDenomCountGroupId":"OG000", "OutcomeDenomCountValue":"11" } ] } } ] }, "OutcomeClassList":{ "OutcomeClass":[ { "OutcomeClassTitle":"Baseline", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"16.86", "OutcomeMeasurementSpread":"3.40" } ] } } ] } },{ "OutcomeClassTitle":"week 2", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"10.71", "OutcomeMeasurementSpread":"4.75" } ] } } ] } },{ "OutcomeClassTitle":"week 3", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"9.81", "OutcomeMeasurementSpread":"4.45" } ] } } ] } },{ "OutcomeClassTitle":"week 4", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"7.33", "OutcomeMeasurementSpread":"2.74" } ] } } ] } },{ "OutcomeClassTitle":"week 5", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"8.35", "OutcomeMeasurementSpread":"4.12" } ] } } ] } },{ "OutcomeClassTitle":"week 6", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"7.73", "OutcomeMeasurementSpread":"3.88" } ] } } ] } },{ "OutcomeClassTitle":"week 7", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"6.28", "OutcomeMeasurementSpread":"5.07" } ] } } ] } },{ "OutcomeClassTitle":"week 8", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"7.36", "OutcomeMeasurementSpread":"4.59" } ] } } ] } } ] } } ] } }, "AdverseEventsModule":{ "EventsFrequencyThreshold":"5", "EventGroupList":{ "EventGroup":[ { "EventGroupId":"EG000", "EventGroupTitle":"Creatine Monohydrate", "EventGroupDescription":"14 female depressed methamphetamine users will receive 5 grams of creatine monohydrate daily for eight weeks.\n\nCreatine monohydrate: Five grams of creatine monohydrate will be administered for eight weeks.", "EventGroupSeriousNumAffected":"0", "EventGroupSeriousNumAtRisk":"14", "EventGroupOtherNumAffected":"14", "EventGroupOtherNumAtRisk":"14" } ] }, "OtherEventList":{ "OtherEvent":[ { "OtherEventTerm":"Cold and flu symptoms", "OtherEventOrganSystem":"General disorders", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"10", "OtherEventStatsNumAtRisk":"14" } ] } },{ "OtherEventTerm":"Indigestion", "OtherEventOrganSystem":"Gastrointestinal disorders", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"14" } ] } },{ "OtherEventTerm":"Polydipsia", "OtherEventOrganSystem":"General disorders", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"14" } ] } },{ "OtherEventTerm":"Headache", "OtherEventOrganSystem":"General disorders", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"14" } ] } },{ "OtherEventTerm":"Swelling in Hands", "OtherEventOrganSystem":"General disorders", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"14" } ] } },{ "OtherEventTerm":"Diarrhea", "OtherEventOrganSystem":"Gastrointestinal disorders", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"4", "OtherEventStatsNumAtRisk":"14" } ] } },{ "OtherEventTerm":"Stomach Discomfort", "OtherEventOrganSystem":"Gastrointestinal disorders", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"3", "OtherEventStatsNumAtRisk":"14" } ] } },{ "OtherEventTerm":"Numbness and Tingling in hands", "OtherEventOrganSystem":"General disorders", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"14" } ] } },{ "OtherEventTerm":"Muscle Cramps", "OtherEventOrganSystem":"General disorders", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"2", "OtherEventStatsNumAtRisk":"14" } ] } },{ "OtherEventTerm":"Lightheaded", "OtherEventOrganSystem":"General disorders", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"14" } ] } },{ "OtherEventTerm":"Nausea", "OtherEventOrganSystem":"General disorders", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"14" } ] } } ] } }, "MoreInfoModule":{ "CertainAgreement":{ "AgreementPISponsorEmployee":"No", "AgreementRestrictiveAgreement":"No" }, "PointOfContact":{ "PointOfContactTitle":"Perry Renshaw, MD, PhD, MBA", "PointOfContactOrganization":"The Brain Institute of the University of Utah", "PointOfContactEMail":"perry.renshaw@hsc.utah.edu", "PointOfContactPhone":"801-587-1216" } } }, "DerivedSection":{ "MiscInfoModule":{ "VersionHolder":"April 22, 2020" }, "InterventionBrowseModule":{ "InterventionBrowseLeafList":{ "InterventionBrowseLeaf":[ { "InterventionBrowseLeafId":"T385", "InterventionBrowseLeafName":"Creatine", "InterventionBrowseLeafAsFound":"Creatine", "InterventionBrowseLeafRelevance":"high" } ] }, "InterventionBrowseBranchList":{ "InterventionBrowseBranch":[ { "InterventionBrowseBranchAbbrev":"Ot", "InterventionBrowseBranchName":"Other Dietary Supplements" },{ "InterventionBrowseBranchAbbrev":"All", "InterventionBrowseBranchName":"All Drugs and Chemicals" } ] } }, "ConditionBrowseModule":{ "ConditionMeshList":{ "ConditionMesh":[ { "ConditionMeshId":"D000019966", "ConditionMeshTerm":"Substance-Related Disorders" },{ "ConditionMeshId":"D000003863", "ConditionMeshTerm":"Depression" },{ "ConditionMeshId":"D000003866", "ConditionMeshTerm":"Depressive Disorder" } ] }, "ConditionAncestorList":{ "ConditionAncestor":[ { "ConditionAncestorId":"D000001526", "ConditionAncestorTerm":"Behavioral Symptoms" },{ "ConditionAncestorId":"D000019964", "ConditionAncestorTerm":"Mood Disorders" },{ "ConditionAncestorId":"D000001523", "ConditionAncestorTerm":"Mental Disorders" },{ "ConditionAncestorId":"D000064419", "ConditionAncestorTerm":"Chemically-Induced Disorders" } ] }, "ConditionBrowseLeafList":{ "ConditionBrowseLeaf":[ { "ConditionBrowseLeafId":"M5641", "ConditionBrowseLeafName":"Depression", "ConditionBrowseLeafAsFound":"Depression", "ConditionBrowseLeafRelevance":"high" },{ "ConditionBrowseLeafId":"M5644", "ConditionBrowseLeafName":"Depressive Disorder", "ConditionBrowseLeafAsFound":"Depression", "ConditionBrowseLeafRelevance":"high" },{ "ConditionBrowseLeafId":"M20421", "ConditionBrowseLeafName":"Substance-Related Disorders", "ConditionBrowseLeafAsFound":"Substance Abuse", "ConditionBrowseLeafRelevance":"high" },{ "ConditionBrowseLeafId":"M3399", "ConditionBrowseLeafName":"Behavioral Symptoms", "ConditionBrowseLeafRelevance":"low" },{ "ConditionBrowseLeafId":"M20419", "ConditionBrowseLeafName":"Mood Disorders", "ConditionBrowseLeafRelevance":"low" },{ "ConditionBrowseLeafId":"M3396", "ConditionBrowseLeafName":"Mental Disorders", "ConditionBrowseLeafRelevance":"low" },{ "ConditionBrowseLeafId":"M13056", "ConditionBrowseLeafName":"Psychotic Disorders", "ConditionBrowseLeafRelevance":"low" },{ "ConditionBrowseLeafId":"M28889", "ConditionBrowseLeafName":"Chemically-Induced Disorders", "ConditionBrowseLeafRelevance":"low" } ] }, "ConditionBrowseBranchList":{ "ConditionBrowseBranch":[ { "ConditionBrowseBranchAbbrev":"BXM", "ConditionBrowseBranchName":"Behaviors and Mental Disorders" },{ "ConditionBrowseBranchAbbrev":"All", "ConditionBrowseBranchName":"All Conditions" },{ "ConditionBrowseBranchAbbrev":"BC25", "ConditionBrowseBranchName":"Substance Related Disorders" } ] } } } } } }